PPI for NSAID gastric prophylaxis in low-risk patients
Use of proton pump inhibitors to prevent NSAID-induced gastropathy in patients without risk factors (age < 65, no ulcer history, no concomitant glucocorticoids or anticoagulants). A category of PPI overuse.
5 drugs
Also known as: PPI prophylaxis in low-risk NSAID users
Marketing claims without evidence base
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
- FEsomeprazoleNot recommended · Drugs for peptic ulcer and GORD. Proton pump inhibitorsPPI prophylaxis is not indicated in patients without risk factors for NSAID-induced gastropathy. Risk factors: age ≥ 65, history of peptic ulcer, history of GI bleeding, concurrent glucocorticoids or anticoagulants, high-dose or combined NSAID use, chronic kidney disease. Routine PPI «cover» without these factors is an overuse category.
- FLansoprazoleNot recommended · Proton pump inhibitor (PPI)Lansoprazole is used prophylactically in low-risk NSAID-gastropathy patients and for unevaluated heartburn. ACG 2022 limits PPIs to patients with confirmed risk factors. In low-risk populations the benefit-risk balance is unfavorable, with long-term use linked to fractures (FDA DSC 2011), hypomagnesemia (FDA DSC 2011), B12 deficiency and CDI (FDA DSC 2012).
- FOmeprazoleNot recommended · Proton pump inhibitorsOmeprazole is widely prescribed as gastric protection for short NSAID courses in patients without GI-bleed risk factors, and for general post-meal discomfort. ACG 2022 and AGA 2022 recommend PPI plus NSAID only with risk factors: age over 60, ulcer history, anticoagulants, antiplatelets, high-dose NSAIDs. The Targownik 2010 BMJ analysis and subsequent systematic reviews show long-term PPI signals: B12 deficiency, hypomagnesemia, fractures (FDA Drug Safety Communications 2010, 2011) and Clostridioides difficile infection (FDA DSC 2012).
- FPantoprazoleNot recommended · Proton pump inhibitorsPantoprazole is a proton pump inhibitor (PPI). It is prescribed for GERD, peptic ulcer, Helicobacter pylori eradication, and gastroprotection with NSAID use in patients at high GI bleeding risk – age over 65, ulcer history, concomitant anticoagulants or corticosteroids (ACG 2022, AGA 2020). In low-GI-bleeding-risk patients on short-term NSAIDs, routine PPI gastroprotection is not justified: long-term PPI use is linked to specific risks – vitamin B12 and magnesium deficiency, elevated risk of intestinal infections (Clostridioides difficile), pneumonia, hip and vertebral fractures (via impaired calcium absorption), and chronic kidney disease. If pantoprazole was prescribed for long-term use without confirmed high GI risk, consider seeking a second opinion.
- FRabeprazoleNot recommended · Proton pump inhibitor (PPI)Rabeprazole is prescribed for gastric protection to healthy people without diagnosed GERD or peptic ulcer, including for single NSAID or antibiotic courses. ACG 2022 and AGA 2022 confine PPIs to patients with GI-bleed risk factors. Systematic low-risk-population use increases fracture, hypomagnesemia, B12-deficiency, CDI and acid-rebound risk.
How to read tiers A–F
Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.
- AStrong evidence – first or second line in international guidelines
- BRecommended in selected cases
- CStudy data contradict each other
- DBenefit not proven, no documented harm
- FDocumented harm, or risk without benefit